Treating hepatitis D with bulevirtide – Real-world experience from 114 patients

Treating hepatitis D with bulevirtide – Real-world experience from 114 patients

Background & Aims: Bulevirtide is a first-in-class entry inhibitor of hepatitis B surface antigen. In July 2020, bulevirtide was conditionally approved for the treatment of hepatitis D, the most severe form of viral hepatitis, which frequently causes end-stage liver disease and hepatocellula...

Full description

Bibliographic Details
Main Authors: Christopher Dietz-Fricke, Frank Tacke, Caroline Zöllner, Münevver Demir, Hartmut H. Schmidt, Christoph Schramm, Katharina Willuweit, Christian M. Lange, Sabine Weber, Gerald Denk, Christoph P. Berg, Julia M. Grottenthaler, Uta Merle, Alexander Olkus, Stefan Zeuzem, Kathrin Sprinzl, Thomas Berg, Florian van Bömmel, Johannes Wiegand, Toni Herta, Thomas Seufferlein, Eugen Zizer, Nektarios Dikopoulos, Robert Thimme, Christoph Neumann-Haefelin, Peter R. Galle, Martin Sprinzl, Ansgar W. Lohse, Julian Schulze zur Wiesch, Jan Kempski, Andreas Geier, Florian P. Reiter, Bernhard Schlevogt, Juliana Gödiker, Wolf Peter Hofmann, Peter Buggisch, Julia Kahlhöfer, Kerstin Port, Benjamin Maasoumy, Markus Cornberg, Heiner Wedemeyer, Katja Deterding
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:JHEP Reports
Subjects:
Hepatitis D
Viral hepatitis
Bulevirtide
Real world experience
Antiviral treatment
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555923000174

Internet

http://www.sciencedirect.com/science/article/pii/S2589555923000174

Similar Items